Cancer, a leading cause of death worldwide, poses significant challenges to contemporary medicine. Despite advancements in surgical, chemotherapeutic, and radiological interventions, recurrence and metastasis remain prevalent. A notable breakthrough is the integration of Adjuvant Immune Stimulants with Cytokine-Induced Killer (CIK) cell therapy, a prospective paradigm shift in oncological treatment that promises enhanced patient outcomes.
